
POLICY DETERMINATION



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Effective date: 12/21/18

Code(s) Description

90697 Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-HibHepB), for intramuscular use

Brief Description of Service:

The U.S. Food and Drug Administration (FDA) approved the pediatric hexavalent vaccine designed to protect against the following six diseases: diphtheria, tetanus, pertussis, polio (poliovirus types 1, 2, and 3), disease caused by *Haemophilus influenzae* type b (Hib), and hepatitis B (DTaP-IPV-Hib-HepB). This vaccine is branded as Vaxelis™.

This vaccine received approval by the U.S. Food & Drug Administration on December 21, 2018. At the June 26, 2019 Advisory Committee on Immunization Practices (ACIP), the ACIP members voted to include DTaP-IPV-Hib-HepB in the federal Vaccines for Children (VFC) program.

Recommendation:

The safety and effectiveness of the pediatric hexavalent vaccine (ie, Vaxelis™) for protection against diphtheria, tetanus, pertussis, poliovirus types 1, 2, and 3, disease caused by *Haemophilus influenzae* type b (Hib), and hepatitis B (DTaP-IPV-Hib-HepB) is established.

References:

1. U.S. Food & Drug Administration; Vaccines, Blood & Biologics; VAXELIS, Approval letter, December 21, 2018. <https://www.fda.gov/vaccines-blood-biologics/vaxelis> (6/22/20)
2. CDC – ACIP recommendations June 2019. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm> (6/22/20)